Exelixis (EXEL) Announces FDA Accepts for Priority Review sNDA for CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
Go back to Exelixis (EXEL) Announces FDA Accepts for Priority Review sNDA for CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
August 6, 2021 10:36 AM EDT
Oppenheimer analyst Silvan Tuerkcan raised the price target on Exelixis (NASDAQ: EXEL) to $30.00 (from $27.00) while maintaining an Outperform rating.
The analyst commented, "EXEL provided 2Q financial results featuring record Cabo sales of $284.2M with continued uptake of nivo + cabo in 1L RCC following FDA... More
